These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 6725512)

  • 1. A double blind study to evaluate the effect of methyldopa on menopausal vasomotor flushes.
    Hammond MG; Hatley L; Talbert LM
    J Clin Endocrinol Metab; 1984 Jun; 58(6):1158-60. PubMed ID: 6725512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Objective evidence that placebo and oral medroxyprogesterone acetate therapy diminish menopausal vasomotor flushes.
    Albrecht BH; Schiff I; Tulchinsky D; Ryan KJ
    Am J Obstet Gynecol; 1981 Mar; 139(6):631-5. PubMed ID: 7211966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of methyldopa on menopausal flushes, skin temperature, and luteinizing hormone secretion.
    Tulandi T; Kinch RA; Guyda H; Mazella L; Lal S
    Am J Obstet Gynecol; 1984 Nov; 150(6):709-12. PubMed ID: 6496591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy of the surgical menopause syndrome with depot medroxyprogesterone acetate and its objective evaluation testing the reaction of the anterior pituitary gland to stimulation with gonadotropin-releasing hormone].
    Boschitsch E; Gitsch E; Spona J
    Wien Klin Wochenschr; 1983 Oct; 95(20):718-24. PubMed ID: 6229096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of menopausal hot flushes by methyldopa. A double blind crossover trial.
    Nesheim BI; Saetre T
    Eur J Clin Pharmacol; 1981; 20(6):413-6. PubMed ID: 7026262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A preliminary evaluation of the effect of lofexidine on vasomotor flushes in post-menopausal women.
    Jones KP; Ravnikar V; Schiff I
    Maturitas; 1985 Jul; 7(2):135-9. PubMed ID: 4033447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of intravenous clonidine on menopausal flushing and luteinizing hormone secretion.
    Tulandi T; Lal S; Kinch RA
    Br J Obstet Gynaecol; 1983 Sep; 90(9):854-7. PubMed ID: 6351899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. alpha-Methyldopa for climacteric hot flushes. A double-blind, randomized, cross-over study.
    Andersen O; Engebretsen T; Solberg VM; Orbo A
    Acta Obstet Gynecol Scand; 1986; 65(5):405-9. PubMed ID: 3535358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in the ratio of bioactive to immunoreactive serum luteinizing hormone during vasomotor flushes and hormonal therapy in postmenopausal women.
    Chang SP; Shoupe D; Kletzky OA; Lobo RA
    J Clin Endocrinol Metab; 1984 May; 58(5):925-9. PubMed ID: 6323519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relation of physiological changes to subjective symptoms in postmenopausal women with and without hot flushes.
    Mashchak CA; Kletzky OA; Artal R; Mishell DR
    Maturitas; 1984 Dec; 6(4):301-8. PubMed ID: 6533433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of transdermal estradiol on hormone and metabolic dynamics over a six-week period.
    Haas S; Walsh B; Evans S; Krache M; Ravnikar V; Schiff I
    Obstet Gynecol; 1988 May; 71(5):671-6. PubMed ID: 3357653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha 2-adrenergic mechanism in menopausal hot flushes.
    Freedman RR; Woodward S; Sabharwal SC
    Obstet Gynecol; 1990 Oct; 76(4):573-8. PubMed ID: 2170883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Menopausal flushes: effect of pituitary gonadotropin desensitization by a potent luteinizing hormone- releasing factor agonist.
    Casper RF; Yen SS
    J Clin Endocrinol Metab; 1981 Nov; 53(5):1056-8. PubMed ID: 6793613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of naloxone on menopausal flushes, skin temperature, and luteinizing hormone secretion.
    Tulandi T; Kinch RA; Guyda H; Maiolo LM; Lal S
    Am J Obstet Gynecol; 1985 Jan; 151(2):277-80. PubMed ID: 2982266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of antihypertensive activity and tolerability of guanfacine and methyldopa.
    Malini PL; Strocchi E; Ambrosioni E; Magnani B
    Int J Clin Pharmacol Res; 1983; 3(1):35-9. PubMed ID: 6384071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of prazosin and methyldopa in essential hypertension: results of a randomized, double-blind, parallel trial.
    Whelton PK; Russell RP; Sova-Schulz K; Wyndham R; Walker WG
    J Cardiovasc Pharmacol; 1979; 1(6 Suppl):S28-37. PubMed ID: 94637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
    Speroff L; Gass M; Constantine G; Olivier S;
    Obstet Gynecol; 2008 Jan; 111(1):77-87. PubMed ID: 18165395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guanabenz versus methyldopa in the therapy of mild-to-moderate hypertension.
    Rosendorff C
    S Afr Med J; 1982 Sep; 62(13):435-7. PubMed ID: 7051365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of medroxyprogesterone acetate to prevent menopausal symptoms.
    Bullock JL; Massey FM; Gambrell RD
    Obstet Gynecol; 1975 Aug; 46(2):165-8. PubMed ID: 1153148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonidine (Dixarit) for menopausal flushing.
    Edington RF; Chagnon JP; Steinberg WM
    Can Med Assoc J; 1980 Jul; 123(1):23-6. PubMed ID: 6998552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.